Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Sep 10;9(1):12950.
doi: 10.1038/s41598-019-49426-0.

Galactomannan and PCR in the Central Nervous System to Detect Invasive Mold Disease - A Retrospective Analysis in Immunocompromised Children

Affiliations

Galactomannan and PCR in the Central Nervous System to Detect Invasive Mold Disease - A Retrospective Analysis in Immunocompromised Children

Thomas Lehrnbecher et al. Sci Rep. .

Abstract

Invasive mold disease (IMD) of the central nervous system (CNS) is a severe infectious complication in immunocompromised patients, but early microbiological diagnosis is difficult. As data on the value of biomarkers in the CNS are scarce, in particular in children, we retrospectively analyzed the performance of galactomannan (GM) and PCR assays in CNS samples of 15 children with proven and probable CNS IMD and of 32 immunocompromised children without fungal infection. Galactomannan in the cerebrospinal fluid (CSF) was assessed in nine of the 15 pediatric patients and was positive in five of them. Polymerase chain reaction (PCR) was performed in eight of the 15 patients and detected nucleic acids from molds in six patients. Galactomannan and PCR in CNS samples were the only positive microbiologic parameter in the CNS in three and two patients, respectively. In four patients, PCR specified the pathogen detected in microscopy. Galactomannan and PCR results remained negative in the CSF of all immunocompromised children without evidence for CNS IMD. Our data suggest that GM and PCR in CNS specimens are valuable additional tools in diagnosing CNS IMD and should be included in the work up of all pediatric patients with suspected mold disease of the CNS.

PubMed Disclaimer

Conflict of interest statement

Prof. Lehrnbecher received personal fees from Gilead Sciences, MSD/Merck and Astellas. In addition, he was given a research grant by Gilead Sciences. Prof. Groll received personal fees from Gilead Sciences, MSD/Merck, Sharp & Dohme, Pfizer and Amplyx. In addition, he was given a research grant by Gilead Sciences. Prof. Lauten received personal fees from MSD/Merck. All other authors have indicated they have no financial relationships relevant to this article to disclose.

Figures

Figure 1
Figure 1
Results of culture, microscopy, and galactomannan (GM) and PCR assays in children with and without proven/probable central nervous system invasive mold disease (CNS IMD).

Similar articles

Cited by

References

    1. Suzuki Y, Togano T, Ohto H, Kume H. Visceral Mycoses in Autopsied Cases in Japan from 1989 to 2013. Med Mycol J. 2018;59:E53–E62. doi: 10.3314/mmj.18-00003. - DOI - PubMed
    1. Schwartz S, Kontoyiannis DP, Harrison T, Ruhnke M. Advances in the diagnosis and treatment of fungal infections of the CNS. Lancet Neurol. 2018;17:362–372. doi: 10.1016/S1474-4422(18)30030-9. - DOI - PubMed
    1. Cornely, O. A. et al. Global guideline for the diagnosis and management of mucormycosis: An initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium Lancet Infect Dis (in press). - PMC - PubMed
    1. Hassler A, Porto L, Lehrnbecher T. Cerebral Fungal Infection in Pediatric Cancer Patients. Current Fungal Infection Reports. 2015;9:6–14. doi: 10.1007/s12281-014-0213-y. - DOI
    1. Lehrnbecher T, Becker K, Groll AH. Current Algorithms in Fungal Diagnosis in the Immunocompromised Host. Methods Mol Biol. 2017;1508:67–84. doi: 10.1007/978-1-4939-6515-1_3. - DOI - PubMed

Publication types

MeSH terms